Carl Zeiss Meditec's price target has been lowered by UBS from 71 euros to 65 euros.
Despite recent underperformance, UBS maintains a "Neutral" rating on the stock.
Analyst Graham Doyle believes that the current investment landscape for the medical technology company is unattractive due to an unfavorable balance between opportunities and risks.
For investors interested in capitalizing on price movements in Carl Zeiss Meditec, there are selected leverage products available that offer leverage between 2 and 20 times.